Pfizer, Valneva to stop testing Lyme disease vaccine in some U.S. patients

By Bhanvi Satija
Feb. 17, 2023

Feb 17 (Reuters) – Drugmaker Pfizer Inc (PFE.N) and France’s Valneva (VLS.PA) will stop testing a Lyme disease vaccine in roughly half of U.S. patients in a late-stage study, the companies said, citing a breach of clinical trial guidelines by a third-party contractor.

The decision could delay the time to approval of a vaccine that Valneva expects could become a blockbuster shot as infections rise globally due to a burgeoning population of ticks, which usually cause Lyme disease.

Valneva has been pinning its hopes on the vaccine candidate, known as VLA15, to counter the impact of disappointing sales for its COVID shot.



I’ll bet Valneva wants to counter the impact of disappointing sales of its COVID jab….

For more:

%d bloggers like this: